- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03011723
Tailored Music Therapy for Dementia
Positive Emotions, Communication and Quality of Life in Dementia: A Tailored Music Therapy Intervention
Study Overview
Status
Intervention / Treatment
Detailed Description
Dementia is often followed by complicating symptoms such as anxiety, depression, agitation, hallucination and sleep disorders. The progression of dementia can threaten the relationship between the person with dementia (PWD) and their relatives. One reason is the possible loss of reciprocity and a mutual supportive relationship. This may influence the quality of life in both the PWD and their relatives and increase the caregiver-burden. The music therapy in this intervention is focusing on increasing positive emotions, increasing reciprocity and stimulating communication.
The 1st, 5th and 10th music therapy-session is video-recorded. The first 5 recorded minutes before the sessions will provide a baseline of the observed primary outcomes throughout the session. Videos are analyzed to examine changes in social communication behavior and emotional well-being. Time-series analysis of the observations will be conducted, enabling us to evaluate potential effects of the therapeutic interventions and to find out when, why and to what extent changes unfold in real time. The pre-post measures are secondary. The project is a merging and further development of two recent music therapy designs. (Articles cited in the references.)
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bergen, Norway, 5009
- NKS Olaviken Alderspsykiatriske sykehus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient is diagnosed with Dementia of the Alzheimer's type, Vascular Dementia, Dementia with Lewy bodies, Parkinsons's Disease Dementia (ICD-10 criteria)
- The severity of the cognitive impairment is within the range of 0,5 - 2 when assessed with The Clinical Dementia Rating Scale (CDR)
- A caregiver chosen by the patient commits to involvement in the treatment as a collateral (i.e. spouse, child, grandchild, sibling, close friend)
- Use of psychotropic medication has been stable during the past 2 weeks
- The PWD is able to answer simple self-report questionnaires on their own or when interviewed by a trained professional
- Informed consent is obtained from patients and caregiver
- The PWD's are living in their home, in assisted living facilities or only periodical living in care homes.
Exclusion Criteria:
- Severe dementia(a score of 3> on CDR).
- Severe aphasia
- Frontotemporal dementia
- Comorbid diagnosis of bipolar disorder, diagnosis of schizophrenia and related disorders
- Changes in psychotropic medications in the past 2 weeks. If so, the medication needs to be stable before pre-assessment is undertaken
- Severe psychotic symptoms or serious risk of suicide
- Permanent living arrangement in nursing home, or planned temporary stay during the treatment period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Music therapy
10 weekly sessions of in-home music therapy for PWDs and a caregiver, including weekly practicing of the interventions with the caregiver between the sessions.
The treatment is administered individually.
|
10 weeks of tailored individual music therapy for PWD and a caregiver. Pre and post assessment in addition. The music therapy consists of one or more of the following activities:
The treatment is following the principles of resource oriented music therapy as described by Rolvsjord et al (2005) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in social interaction behavior throughout the music therapy session compared to baseline(Verbal and Nonverbal Interaction Scale (VNVIS))
Time Frame: Baseline (the first 5 videorecorded minutes before the music therapy) up to 45 minutes with music therapy intervention. The 1st, 5th and 10th session is videorecorded. Observation-interval is 30 seconds.
|
Verbal and nonverbal interaction scale(VNVIS) is a standardized observational instrument for assessing prosocial and nonsocial verbal and nonverbal communication behavior between a person with dementia and their close caregiver.
The scale is measuring both prosocial and nonsocial behavior, 26 items, 13 pr subscale.
The person can score from 0-13 points on prosocial items pr timepoint, higher score indicates more prosocial behavior is present.
The same holds for nonsocial behavior, the higher score indicates more nonsocial behavior observed.
|
Baseline (the first 5 videorecorded minutes before the music therapy) up to 45 minutes with music therapy intervention. The 1st, 5th and 10th session is videorecorded. Observation-interval is 30 seconds.
|
Observable signs of well being (OSWDS)
Time Frame: Baseline (the first 5 videorecorded minutes before the music therapy) up to 45 minutes with music therapy intervention. The 1st, 5th and 10th session is videorecorded. Observation-interval is 30 seconds.
|
The observable signs of wellbeing in dementia- scale (OSWDS) is a scale for proxy-rated well being in persons with dementia.
The scale is under development, and is tested during the intervention.
It consists of 10 items measuring from 0-10 points.
Each item is rated as present or non-present during the time interval.
Higher score indicates higher levels of observed wellbeing.
|
Baseline (the first 5 videorecorded minutes before the music therapy) up to 45 minutes with music therapy intervention. The 1st, 5th and 10th session is videorecorded. Observation-interval is 30 seconds.
|
Change in self reported mood before and after the music therapy session (Visual Analogue Mood Scale (VAMS))
Time Frame: Assessment before and after every music therapy session (10 weeks) and before and after every musical activity with the relative (10 weeks)
|
VAMS is a standardized visual analogue scale tailored to persons with cognitive impairment measuring 8 self reported mood states.
Each state is scored by marking on a 10 cm line by the person with dementia.
The score is calculated by measuring the point on the line in mm, and the range is 0-100, were 100 indicates maximum emotional experience.
|
Assessment before and after every music therapy session (10 weeks) and before and after every musical activity with the relative (10 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Neuropsychiatric symptoms (NPI-Q)
Time Frame: Baseline and post-treatment (up to two weeks after the intervention period)
|
NPI-Q is a standardized measure of common neuropsychiatric symptoms following dementia.
The scale consists of 12 items rated from 0-3.
Items are summed, and the range is 0-36.
Higher score means more severe neuropsychiatric symptoms.
|
Baseline and post-treatment (up to two weeks after the intervention period)
|
Change in Quality of life in Alzheimer Dementia (QoL-AD)
Time Frame: Baseline and post-treatment (up to two weeks after the intervention period)
|
QoL-AD is a standardized interview designed to measure items concerning the experienced quality of life in persons with dementia.
The scale consists of 15 items from 1-4.
The items are summed, and the range is 15-60.
Higher score means higher self-reported quality of life.
|
Baseline and post-treatment (up to two weeks after the intervention period)
|
Change in Relative Stress Scale (RSS)
Time Frame: Baseline and post-treatment (up to two weeks after the intervention period)
|
RSS is a standardized measure of self-reported caregiver burden in carers of PWD. 15 items are scored from 0-4, giving a range from 0-60.
A higher score indicates more severe stress for the caregiver.
|
Baseline and post-treatment (up to two weeks after the intervention period)
|
Change in Music in Dementia Assessment Scales (MiDAS)
Time Frame: Before and after every music therapy session (10 weeks)
|
MiDAS is a standardized music therapy outcome scale measuring clinical response to the intervention.
The scale consists of 5 items on a visual analogue scale, and the music therapist score the items for the 5 first minutes and for the 5 most significant minutes in the session.
Each item has a range from 0-100, were a higher score means a higher level of involvement in the music therapy.
The 5 items are reviewed separately.
|
Before and after every music therapy session (10 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mini Mental Status Examination (MMSE)
Time Frame: Baseline
|
Screening instrument for cognitive impairment.
The scale consists of 30 questions and tasks.
The range is 0-30 points, were a higher score indicates higher cognitive functions.
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Inger Hilde Nordhus, Professor, PhD, University of Bergen
Publications and helpful links
General Publications
- Shall A, Haberstroh J, Pantel J. Time series analysis of individual music therapy in dementia. Effects on communication behavior and emotional well-being. Gero Psych 28 (3): 113-122, 2015
- Baker FA, Grocke D, Pachana NA, Clair AA. Connecting through music: a study of a spousal caregiver-directed music intervention designed to prolong fulfilling relationships in couples where one person has dementia. Australian Journal of Music Therapy, 23: 4-21, 2012.
- Rolvsjord R, Gold C, Stige B. Research rigour and therapeutic flexibility: Rationale for a therapy manual developed for a randomised controlled trial. Nordic Journal of Music Therapy 14(1), 15-32, 2005.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Neurocognitive Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Tauopathies
- Intracranial Arterial Diseases
- Intracranial Arteriosclerosis
- Leukoencephalopathies
- Parkinson Disease
- Dementia
- Alzheimer Disease
- Lewy Body Disease
- Dementia, Vascular
Other Study ID Numbers
- UBergen 2016/1374
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia, Vascular
-
Samsung Medical CenterDong-A Pharmaceutical Co., Ltd.UnknownVascular Dementia | Subcortical Vascular DementiaKorea, Republic of
-
University Health Network, TorontoCompleted
-
Maastricht University Medical CenterCompletedVascular Dementia | Post-stroke Depression | Vascular Cognitive Impairment | Post-stroke Apathy | Post-stroke DementiaNetherlands
-
Charsire Biotechnology Corp.CompletedAlzheimer's Disease or Vascular DementiaUnited States
-
Tianjin Medical University General HospitalUnknownCerebral Small Vessel Diseases | Subcortical Vascular DementiaChina
-
Yamei TangRecruitingCognitive Impairment | Alzheimer Disease | MCI | VAD - Vascular DementiaChina
-
Merz Pharmaceuticals GmbHLLC Merz Pharma, RussiaCompleted
-
Dongzhimen Hospital, BeijingCompletedVascular DementiaChina
-
Peking University First HospitalZhejiang Otsuka Pharmaceutical Co., Ltd.CompletedStroke | Vascular DementiaChina
-
Eisai Inc.Eisai Co., Ltd.CompletedVascular DementiaPhilippines
Clinical Trials on Resource oriented music therapy
-
NORCE Norwegian Research Centre ASThe Research Council of Norway; Helse Stavanger HF; Helse Vest; Helse Forde; University... and other collaboratorsCompletedPersonality Disorders | Mental Disorders | Mood Disorders | Schizophrenia and Disorders With Psychotic FeaturesNorway, Australia, Austria
-
REHPA, The Danish Knowledge Centre for Rehabilitation...University of Southern DenmarkCompleted
-
University of LahoreCompleted
-
McGill UniversityRecruitingCritical Illness | Pain, Acute | Distress, EmotionalCanada
-
University of MichiganNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedMental Health | Alcohol; Use, Problem | Physical Health | Interpersonal ViolenceUnited States
-
Case Comprehensive Cancer CenterCompletedMultiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin LymphomaUnited States
-
National Center for Complementary and Integrative...CompletedPost-Traumatic Stress Disorder | Dissociation | Child Abuse, SexualUnited States
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteCompletedAutonomic Nervous System Imbalance | Hypothalamic Pituitary Adrenal Axis SuppressionUnited States
-
Wayne State UniversityCompletedNeurological DisordersUnited States
-
Icahn School of Medicine at Mount SinaiCompletedSARS-CoV 2 | Dyspnea | Post Covid-19 RespiratoryUnited States